Nebula Genomics

BioBam Releases OmicsBox 2.2, The Latest Update of its Bioinformatics Software Solution

Retrieved on: 
Mercoledì, Settembre 21, 2022
Software, Biometrics, Biotechnology, Data Analytics, Health, Professional Services, Technology, Genetics, Blast2GO, Algorithm, Molecular biology, Single cell, CPU, Functional analysis, BioBam Bioinformatics, Computational biology, Data analysis, Nebula Genomics, CEO, NGS, Genomics, Research, Multimedia, Gene expression, Microbiology, Metagenomics, Mobile phone, Computer data storage

This new version of BioBams bioinformatics solution offers new Single Cell and Long Read Data Analysis Features among other platform improvements.

Key Points: 
  • This new version of BioBams bioinformatics solution offers new Single Cell and Long Read Data Analysis Features among other platform improvements.
  • This release also positions BioBam as a key player among Long-Read and Single-Cell data analysis solution providers.
  • OmicsBox is a bioinformatics solution that allows to easily get from sequencing reads to insights.
  • BioBam is dedicated to creating bioinformatics software solutions that assist researchers in their daily data analysis tasks.

ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

Retrieved on: 
Martedì, Settembre 6, 2022
COVID-19, University, RT-PCR, Food, OTC, FDM, Research, Gene, Prophase, NASDAQ, LB-2, Dietary supplement, Media relations, Board, DNA, Inherited disorders of trafficking, LB-1, Laboratory, Genomics, Madison Avenue, CLIA, Severe acute respiratory syndrome coronavirus 2, PCR, GLOBE, COVID-19 testing, TK, Conference, Nasdaq, Company, Nebula Genomics, Eastern Time Zone, Lotte New York Palace Hotel, Chromosome, Director, Growth, Acquisition, PIM, Marketing, Vaccine

The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

Key Points: 
  • The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
  • ProPhase Labs CEO and Chairman of the Board of Directors, Ted Karkus, will be presenting in person and will provide an overview of the Company's business during the presentation.
  • If you are an institutional investor, and would like to listen to the Companys presentation, please click on the following link ( www.hcwevents.com/annualconference ) to register for the conference.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

LifeVantage Declares Quarterly Dividend

Retrieved on: 
Martedì, Agosto 23, 2022
Security (finance), COVID-19, Research, Gene, Hair, Protandim, Nebula Genomics, Dietary supplement, Sale, Risk, SALT, Dog, Optimism, Skin, U.S. Securities and Exchange Commission, GLOBE, Company, Annual report, Private Securities Litigation Reform Act, Growth, Health, Oxidative stress, Risk management

SALT LAKE CITY, Aug. 23, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced that the Companys Board of Directors has approved a quarterly cash dividend of $0.03 per share of common stock, which will be paid September 15, 2022 to all stockholders of record at the close of business on September 2, 2022.

Key Points: 
  • SALT LAKE CITY, Aug. 23, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced that the Companys Board of Directors has approved a quarterly cash dividend of $0.03 per share of common stock, which will be paid September 15, 2022 to all stockholders of record at the close of business on September 2, 2022.
  • LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
  • The Companys line of scientifically-validated dietary supplements includes its flagship Protandim family of products, LifeVantage Omega+, ProBio, and Daily Wellness dietary supplements, TrueScience is the Company's line of skin, hair, bath & body, and targeted relief products.
  • LifeVantage was founded in 2003 and is headquartered in Lehi, Utah.

Vector Space Biosciences Announces New Tools for Developing Countermeasures Associated to Stressors During Spaceflight

Retrieved on: 
Giovedì, Agosto 18, 2022
Other Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Science, Biotechnology, Aerospace, Other Technology, Manufacturing, Other Science, Health, Transfer, Machine learning, API, Decentralized autonomous organization, DNA repair, Intelligence, Nanotechnology, Ray (optics), Precision medicine, Gene, Application, Natural language, GCR, Vector space, United States National Library of Medicine, Artemis, Gene expression, Cancer, LEO, Chromosomal translocation, Natural language processing, Protein, National library, Artificial intelligence, Research, AlphaFold, Human, Radiobiology evidence for protons and HZE nuclei, Muscle atrophy, Micronutrient, Nebula Genomics, DNA, BERT, Linear energy transfer, ECM, PubMed, Radiation, TME, Biotechnology, Tumor microenvironment, Exosome, Ageing, Organic acid, Maintenance, Phytochemical, Health, ML, Medical device, Fine chemical

Countermeasures against diseases associated to stressors during spaceflight, such as microgravity and radiation, need to be developed quickly.

Key Points: 
  • Countermeasures against diseases associated to stressors during spaceflight, such as microgravity and radiation, need to be developed quickly.
  • As the new space race heats up, more humans will be traveling to space than ever before.
  • Each experiment and launch is funded by public and private entities, individuals and members of Vector Space Biosciences DAO (Decentralized Autonomous Organization), SpaceBioDAO.
  • Vector Space Biosciences enables researchers in space biosciences, biotechnology and pharmaceutical development to capture changes in these relationships in real-time.

LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2022 Results on August 23, 2022

Retrieved on: 
Martedì, Agosto 9, 2022
Daily, Gene, Oxidative stress, Investor relations, GLOBE, Dog, Sale, Research, Nebula Genomics, Company, Protandim, Nootropic, Skin, Webcast, Hair, SALT, Bath & Body Works, Dietary supplement, Health

SALT LAKE CITY, Aug. 09, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2022, after the stock market closes on Tuesday, August 23, 2022.

Key Points: 
  • SALT LAKE CITY, Aug. 09, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2022, after the stock market closes on Tuesday, August 23, 2022.
  • The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
  • Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920.
  • LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of hownutrition and naturally occurring compounds affect human genes to support good health.

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time

Retrieved on: 
Venerdì, Agosto 5, 2022
Genomics, Laboratory, Nebula Genomics, Gene, FDM, Inherited disorders of trafficking, Research, Chromosome, Marketing, DNA, RT-PCR, Company, COVID-19, Food, Acquisition, OTC, Prophase, University, LB-2, Nasdaq, PCR, Severe acute respiratory syndrome coronavirus 2, LB-1, CLIA, PIM, Dietary supplement, COVID-19 testing, TK, Vaccine

The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing.

Key Points: 
  • The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing.
  • Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • We have announced plans for the expansion of the lab to include traditional clinical testing and genomics testing.

ProPhase Labs Announces New $6 Million Stock Repurchase Plan

Retrieved on: 
Martedì, Luglio 26, 2022
Dietary supplement, Income, FDM, Laboratory, Securities Exchange Act of 1934, Marketing, TK, Gene, Company, Board of directors, Perception, PCR, OTC, EBITDA, Acquisition, Inherited disorders of trafficking, Food, Severe acute respiratory syndrome coronavirus 2, Investment, Environment, Genomics, Research, Chromosome, LB2, Generally Accepted Accounting Principles (United States), LB-1, Technology, COVID-19 testing, Program, DNA, CLIA, GLOBE, SEC, Failure, Board, PIM, COVID-19, Prophase, Confusion, Net income, Linebacker, Nasdaq, RT-PCR, LB-2, Institution, Adjustment, Risk, Name, Forecasting, Time, Trial of the century, History, Private Securities Litigation Reform Act, University, NASDAQ, GAAP, Burn, Nebula Genomics, Depreciation, Security (finance), Pharmaceutical industry, Bank

Garden City, NY, July 26, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock, which will become effective three business days after the date the Company issues its quarterly earnings release for the six months ended June 30, 2022 (the “Commencement Date”), which the Company currently anticipates issuing on August 12, 2022.

Key Points: 
  • The Company expects to utilize its existing funds to fund repurchases under the repurchase program.
  • Our four operating divisions, ProPhase Diagnostics, ProPhase Precision Medicine (parent company to Nebula Genomics), Pharmaloz Manufacturing and TK Supplements are all growing year-over-year and generating positive earnings.
  • Our goal for ProPhase BioPharma is to commence animal studies immediately for Linebacker-1 (LB-1) as a potential cancer co-therapy followed by an initial human clinical study.
  • We estimate 12 to 18 months to complete both at a cost of approximately $5 million.

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Giovedì, Luglio 21, 2022
Dietary supplement, DNA, Acquisition, CLIA, Food, Severe acute respiratory syndrome coronavirus 2, FDM, GLOBE, Genomics, Laboratory, Research, Chromosome, University, Marketing, TK, Prophase, PIM, NASDAQ, COVID-19, Gene, LB-1, COVID-19 testing, Company, Nebula Genomics, Nasdaq, RT-PCR, LB-2, Institution, PCR, Employment, OTC, Pharmaceutical industry, Antibiotics

This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Companys stockholder approved equity plan.

Key Points: 
  • This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Companys stockholder approved equity plan.
  • The options have an exercise price of $13.00 per share and will be exercisable for a period of 7 years.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase Labs actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

ProPhase Labs to Host Live Webcast to Discuss Business Developments on Thursday, July 21, 2022

Retrieved on: 
Martedì, Luglio 19, 2022
Research, Nebula Genomics, Severe acute respiratory syndrome coronavirus 2, Acquisition, CLIA, Nasdaq, Review, Institution, Director, GLOBE, DNA, Genomics, Food, TK, RT-PCR, FDM, Marketing, PST, Gene, NASDAQ, PCR, Dietary supplement, Board, COVID-19 testing, COVID-19, EST, Chromosome, Company, Laboratory, Webcast, OTC, Prophase, University, Antibiotics, Vaccine

Garden City, NY, July 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it will host a live webcast on Thursday, July 21, 2022, at 11:30 a.m. EST / 8:30 a.m. PST.

Key Points: 
  • Garden City, NY, July 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it will host a live webcast on Thursday, July 21, 2022, at 11:30 a.m. EST / 8:30 a.m. PST.
  • ProPhase Labs CEO and Chairman of the Board of Directors, Ted Karkus, will host the webcast and review the latest developments at ProPhase Labs and its subsidiaries.
  • To access the call, please use the following information:
    Participants can register for the webcast by navigating to:
    Pre-registration required fields of information include: name and email.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

Retrieved on: 
Martedì, Giugno 28, 2022
EHF, EVD, Research, Polyphenol, GLOBE, RT-PCR, Marketing, COVID-19, Laboratory, Chromosome, TK, Genomics, CLIA, World, DSS, Environment, IND, Prophase, Nebula Genomics, Federal Food, Drug, and Cosmetic Act, GRAS, Severe acute respiratory syndrome coronavirus 2, FDA, University, Gene, Food, LLC, SEC, Risk, Solution, Global, Institution, Acquisition, OTC, Biotechnology, Infection, Dietary supplement, COVID-19 testing, Baxter International, Private Securities Litigation Reform Act, Nasdaq, Health, NASDAQ, PCR, Drug discovery, Ebola, Gallic acid, Inherited disorders of trafficking, FDM, R, Charles River Laboratories, Degenerative disease, Mass, World Health Organization, DNA, Human, Safety, Vaccine, Pharmaceutical industry, Antibiotics, Company, Rhinovirus, Gallic

Garden City, NY, June 28, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced the formation of wholly-owned subsidiary ProPhase BioPharma, Inc. (PBIO) for the licensing and development of novel drugs, compounds and biotechnology. PBIO will focus on advanced technology in the biochemical industry and creating and formulating new compounds that can change the outcomes of healthcare.

Key Points: 
  • Under the terms of the agreement, ProPhase Labs has obtained exclusive rights worldwide to develop and commercialize Equivir and Equivir G.
    We are thrilled to announce the formation of ProPhase BioPharma, our new wholly-owned subsidiary tasked with licensing and developing novel drugs, compounds and biotechnology.
  • We also look forward to applying to the FDA for an IND for Equivir G as a prescription antiviral.
  • The agreement between ProPhase Labs and Global BioLife comes just prior to the commencement of human clinical trials for Equivir.
  • ProPhase is currently in contact with leading clinical research organizations to initiate these trials in the coming months.